Last update 30 Jan 2025

Alesta Therapeutics

Holding Company|
Netherlands
|
www.alestatherapeutics.com

Overview

Tags

Other Diseases
Congenital Disorders
Nervous System Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases1
Neoplasms1
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Small molecule drug3
Top 5 TargetCount
EIF2AK4(eukaryotic translation initiation factor 2 alpha kinase 4)1

Related

3
Drugs associated with Alesta Therapeutics
ALE2
Target-
Mechanism-
Active Org.
Alesta Therapeutics
Originator Org.
Alesta Therapeutics
Active Indication
Charcot-Marie-Tooth Disease
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
ALE1
Target-
Mechanism-
Active Org.
Alesta Therapeutics
Originator Org.
Alesta Therapeutics
Active Indication
Hypophosphatasia
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
ALE-001
Target
EIF2AK4
Mechanism
EIF2AK4 modulators
Active Org.
Alesta Therapeutics
Originator Org.
Alesta Therapeutics
Active Indication
Solid tumor
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
100 Clinical Results associated with Alesta Therapeutics
Login to view more data
0 Patents (Medical) associated with Alesta Therapeutics
Login to view more data
100 Deals associated with Alesta Therapeutics
Login to view more data
100 Translational Medicine associated with Alesta Therapeutics
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 28 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
3
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
ALE1
Hypophosphatasia
More
Preclinical
ALE-001
 ( EIF2AK4 )		Solid tumor
More
Preclinical
ALE2
Charcot-Marie-Tooth Disease
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free